Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
12/10/2026 17:32
BRIEF-Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84 Oct 12 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:
REGENERON PHARMACEUTICALS - PASATRU SHOWS SUSTAINED EFFICACY AND CONSISTENT SAFETY PROFILE FROM WEEKS 56 TO 84
REGENERON PHARMACEUTICALS - PASATRU MAINTAINS WELL-TOLERATED SAFETY PROFILE THROUGH WEEK 84
Source text: ID:nGNX8vHQdh
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement